Wall Street Zen cut shares of Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) from a sell rating to a strong sell rating in a report published on Saturday morning,Wall Street Zen reports.
Other equities analysts also recently issued research reports about the company. JPMorgan Chase & Co. decreased their target price on Enanta Pharmaceuticals from $19.00 to $17.00 and set an “overweight” rating for the company in a report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Thursday, October 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Enanta Pharmaceuticals in a research note on Wednesday, September 23rd. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Enanta Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $19.00.
View Our Latest Research Report on Enanta Pharmaceuticals
Enanta Pharmaceuticals Stock Performance
Shares of ENTA opened at $7.62 on Friday. Enanta Pharmaceuticals has a fifty-two week low of $7.56 and a fifty-two week high of $17.15. The firm has a 50 day moving average price of $11.48 and a 200-day moving average price of $12.97. The firm has a market cap of $222.20 million, a price-to-earnings ratio of -3.24 and a beta of 0.75.
Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) last announced its quarterly earnings results on Monday, November 16th. The biotechnology company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.09). Enanta Pharmaceuticals had a negative return on equity of 64.32% and a negative net margin of 108.33%. The company had revenue of $12.87 million during the quarter, compared to analysts’ expectations of $14.62 million. As a group, equities research analysts predict that Enanta Pharmaceuticals will post -2.24 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. Legal & General Group Plc purchased a new stake in shares of Enanta Pharmaceuticals in the 2nd quarter worth $41,000. Clearstead Trust LLC purchased a new stake in shares of Enanta Pharmaceuticals during the second quarter valued at $74,000. Northeast Investment Management bought a new stake in Enanta Pharmaceuticals during the 3rd quarter valued at $132,000. Bank of America Corp DE bought a new position in Enanta Pharmaceuticals in the second quarter worth approximately $314,000. Finally, Deutsche Bank AG bought a new position in Enanta Pharmaceuticals in the second quarter worth about $408,000. Hedge funds and other institutional investors own 94.99% of the company’s stock.
More Enanta Pharmaceuticals News
Here’s some of the latest news about ENTA:
- Positive Sentiment: HC Wainwright maintained its Buy rating and $20 price target, while raising its FY2027–FY2030 earnings estimates to reflect smaller projected losses. This signals improved longer-term expectations, though the forecasts still show losses. MarketBeat report
- Neutral Sentiment: JPMorgan cut its price target to $17 from $19 but kept an Overweight rating. The lower target is a negative revision, while the rating and implied upside from the cited $7.62 share price remain supportive.
- Negative Sentiment: Enanta’s latest reported quarter missed expectations: its loss per share was wider than analysts forecast, and revenue came in below estimates. The results may weigh on sentiment amid the analyst updates. MarketBeat earnings information
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc. is a biotechnology company based in Watertown, Massachusetts, that discovers and develops small-molecule medicines. Its research has focused on infectious diseases and inflammatory conditions, including respiratory syncytial virus (RSV), hepatitis B and immunology. Enanta’s work with AbbVie contributed to the discovery of glecaprevir, an antiviral used with pibrentasvir in the hepatitis C treatment Mavyret. The collaboration reflects the company’s history of applying its drug-discovery expertise to antiviral therapies.
Recommended Stories
- Five stocks we like better than Enanta Pharmaceuticals
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
